[go: up one dir, main page]

MXPA05008601A - Derivados de benzamida como agonistas de oxitocina y antagonistas de vasopresina. - Google Patents

Derivados de benzamida como agonistas de oxitocina y antagonistas de vasopresina.

Info

Publication number
MXPA05008601A
MXPA05008601A MXPA05008601A MXPA05008601A MXPA05008601A MX PA05008601 A MXPA05008601 A MX PA05008601A MX PA05008601 A MXPA05008601 A MX PA05008601A MX PA05008601 A MXPA05008601 A MX PA05008601A MX PA05008601 A MXPA05008601 A MX PA05008601A
Authority
MX
Mexico
Prior art keywords
benzamide derivatives
vasopressin antagonists
oxytocin agonists
agonists
oxytocin
Prior art date
Application number
MXPA05008601A
Other languages
English (en)
Inventor
Peter Andrew Robson
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MXPA05008601A publication Critical patent/MXPA05008601A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compuestos novedosos de conformidad con la formula general 1, en donde G1 es NR5R6 o un grupo policiclico fusionado, que son agonistas especificos del receptor de OT y/o antagonistas especificos del receptor V1a. Las composiciones farmaceuticas que comprenden estos compuestos son utiles en el tratamiento, inter alia, de la dismenorrea primaria (ver formula).
MXPA05008601A 2003-02-14 2004-02-12 Derivados de benzamida como agonistas de oxitocina y antagonistas de vasopresina. MXPA05008601A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03003394A EP1449844A1 (en) 2003-02-14 2003-02-14 benzamide derivatives as oxytocin agonists and vasopressin antagonists
PCT/EP2004/001304 WO2004072083A1 (en) 2003-02-14 2004-02-12 Benzamide derivatives as oxytocin agonists and vasopressin antagonists

Publications (1)

Publication Number Publication Date
MXPA05008601A true MXPA05008601A (es) 2005-11-04

Family

ID=32731527

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008601A MXPA05008601A (es) 2003-02-14 2004-02-12 Derivados de benzamida como agonistas de oxitocina y antagonistas de vasopresina.

Country Status (13)

Country Link
US (2) US7407949B2 (es)
EP (2) EP1449844A1 (es)
JP (1) JP2006517530A (es)
KR (1) KR100725560B1 (es)
CN (1) CN100349896C (es)
AU (1) AU2004212140B2 (es)
CA (1) CA2513220A1 (es)
MX (1) MXPA05008601A (es)
NO (1) NO20054225L (es)
NZ (1) NZ540768A (es)
PL (1) PL379702A1 (es)
RU (1) RU2340617C2 (es)
WO (1) WO2004072083A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000079D0 (en) 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents
EP1632494A1 (en) 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
KR20080063848A (ko) * 2005-10-24 2008-07-07 와이어쓰 옥시토신 수용체 작용제로 유용한 트리사이클릭 화합물
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
RU2557658C2 (ru) * 2009-09-28 2015-07-27 Ф.Хоффманн-Ля Рош Аг Бензоксепиновые ингибиторы pi3 и способы применения
GB201004677D0 (en) 2010-03-19 2010-05-05 Vantia Ltd New salt
CN102905720A (zh) 2010-05-18 2013-01-30 日内瓦大学 催产素样分子的新用途及相关的方法
ES2595251T3 (es) 2010-05-25 2016-12-28 Inserm - Institut National De La Santé Et De La Recherche Médicale Métodos y composición farmacéutica para el tratamiento de un trastorno alimentario con inicio temprano en un paciente
KR102561721B1 (ko) 2016-12-12 2023-07-28 키녹시스 테라퓨틱스 피티와이 리미티드 비펩티드성 옥시토신 수용체 작용제
US11033601B2 (en) 2017-09-14 2021-06-15 The Regents Of The University Of Colorado, A Body Corporate Selective inhibition of V1b for treating fatty liver

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760031A (en) * 1993-07-29 1998-06-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AR011913A1 (es) * 1997-03-06 2000-09-13 Yamano Masaki Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
GB2326639A (en) * 1997-06-18 1998-12-30 Merck & Co Inc Piperazine Oxytocin Receptor Antagonists
US7326700B2 (en) * 2001-04-12 2008-02-05 Wyeth Cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
GB0115515D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Oxytocin agonisys
GB0120051D0 (en) * 2001-08-16 2001-10-10 Ferring Bv Oxytocin agonists

Also Published As

Publication number Publication date
KR100725560B1 (ko) 2007-06-08
CA2513220A1 (en) 2004-08-26
PL379702A1 (pl) 2006-11-13
NO20054225L (no) 2005-11-14
RU2340617C2 (ru) 2008-12-10
US7407949B2 (en) 2008-08-05
RU2005122323A (ru) 2006-02-27
CN1751050A (zh) 2006-03-22
AU2004212140B2 (en) 2006-12-21
KR20050098931A (ko) 2005-10-12
EP1592693A1 (en) 2005-11-09
US20060166971A1 (en) 2006-07-27
WO2004072083A1 (en) 2004-08-26
JP2006517530A (ja) 2006-07-27
NZ540768A (en) 2008-05-30
CN100349896C (zh) 2007-11-21
NO20054225D0 (no) 2005-09-12
US20080275026A1 (en) 2008-11-06
AU2004212140A1 (en) 2004-08-26
EP1449844A1 (en) 2004-08-25

Similar Documents

Publication Publication Date Title
BE2017C018I2 (es)
TNSN07235A1 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
IL177291A0 (en) Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
TW200505903A (en) CGRP receptor antagonists
EP1796678A4 (en) Carboxamide-spirolactam CGRP Receptor Antagonists
NO20053794L (no) N-(1-benzyl-2-oxo-2-(1-piperazinyl) etyl)-1-piperidinkarboksamid-derivater og relaterte forbindelsers bruk som CGRP-antagonister for behandling av hodepine.
ATE466860T1 (de) Cgrp-rezeptorantagonisten
MXPA05011411A (es) 1,4-diazepinas sustituidas y usos de las mismas.
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
DK1399436T3 (da) Oxytocinagonister
PL1620425T3 (pl) Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu
TW200606151A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
ATE413388T1 (de) Muskarin antagonisten
YU30902A (sh) Novi ciklopropani kao cgrp antagonisti, lekovi koji sadrže navedena jedinjenja i postupak za njihovu proizvodnju
MXPA05008601A (es) Derivados de benzamida como agonistas de oxitocina y antagonistas de vasopresina.
TNSN07006A1 (en) Novel heterocyclic compounds
NO20052520L (no) Nye sulfamider
TW200628153A (en) Novel compounds
GB0407025D0 (en) Novel compounds
ATE550326T1 (de) Als modulatoren von hdl einsetzbare verbindungen
TW200716597A (en) Novel piperidine-substituted indoles
GB0519760D0 (en) Novel compounds
MY143862A (en) Piperidine-substituted indoles-or heteroderivatives thereof
MXPA05006587A (es) Compuestos de tiazol como derivados de antagonistas del receptor de la integrina.
MXPA04004980A (es) Antagonistas del receptor ccr-3.

Legal Events

Date Code Title Description
FG Grant or registration